Legal & General Group PLC Kura Oncology, Inc. Transaction History

Legal & General Group PLC

  • $431 Billion
  • Q3 2025

A detailed history of Legal & General Group PLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 78,350 shares of KURA stock, worth $877,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,350
Previous 72,910 7.46%
Holding current value
$877,520
Previous $420,000 65.0%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
BUY
$5.54 - $9.05 $30,137 - $49,232
5,440 Added 7.46%
78,350 $693,000
Q2 2025

Aug 12, 2025
BUY
$5.55 - $6.92 $105,061 - $130,995
18,930 Added 35.07%
72,910 $420,000
Q4 2024

Feb 13, 2025
SELL
$8.51 - $19.21 $39,682 - $89,576
-4,663 Reduced 7.95%
53,980 $470,000
Q3 2024

Feb 28, 2025
BUY
$18.57 - $23.23 $2,042 - $2,555
110 Added 0.2%
54,090 $1.06 Million
Q3 2024

Nov 14, 2024
SELL
$18.57 - $23.23 $29,897 - $37,400
-1,610 Reduced 2.67%
58,643 $1.15 Million
Q2 2024

May 29, 2025
BUY
$17.53 - $22.98 $48,785 - $63,953
2,783 Added 5.26%
55,700 $1.15 Million
Q2 2024

Aug 14, 2024
BUY
$17.53 - $22.98 $128,600 - $168,581
7,336 Added 13.86%
60,253 $1.24 Million
Q1 2024

May 29, 2025
SELL
$13.42 - $23.53 $14,265 - $25,012
-1,063 Reduced 1.97%
52,917 $1.13 Million
Q1 2024

May 14, 2024
SELL
$13.42 - $23.53 $8,964 - $15,718
-668 Reduced 1.25%
52,917 $1.13 Million
Q4 2023

May 29, 2025
SELL
$7.58 - $14.38 $2,994 - $5,680
-395 Reduced 0.73%
53,585 $770,000
Q3 2023

Nov 14, 2023
SELL
$8.44 - $11.86 $1,046 - $1,470
-124 Reduced 0.23%
53,585 $488,000
Q2 2023

Aug 14, 2023
BUY
$9.62 - $13.99 $187,955 - $273,336
19,538 Added 57.18%
53,709 $568,000
Q1 2023

May 15, 2023
BUY
$10.71 - $14.6 $126,356 - $172,250
11,798 Added 52.73%
34,171 $417,000
Q4 2022

Feb 14, 2023
BUY
$11.23 - $16.9 $9,624 - $14,483
857 Added 3.98%
22,373 $277,000
Q3 2022

Nov 14, 2022
BUY
$12.01 - $19.45 $12,598 - $20,403
1,049 Added 5.13%
21,516 $294,000
Q2 2022

Aug 22, 2022
BUY
$10.71 - $18.33 $13,119 - $22,454
1,225 Added 6.37%
20,467 $376,000
Q3 2021

Nov 15, 2021
BUY
$15.42 - $21.72 $171,516 - $241,591
11,123 Added 137.0%
19,242 $360,000
Q2 2021

Aug 12, 2021
SELL
$20.85 - $29.88 $36,320 - $52,050
-1,742 Reduced 17.67%
8,119 $169,000
Q1 2021

May 17, 2021
BUY
$24.75 - $39.14 $11,162 - $17,652
451 Added 4.79%
9,861 $278,000
Q4 2020

Feb 12, 2021
BUY
$29.0 - $41.62 $26,303 - $37,749
907 Added 10.67%
9,410 $307,000
Q3 2020

Nov 13, 2020
SELL
$16.3 - $30.64 $37,653 - $70,778
-2,310 Reduced 21.36%
8,503 $261,000
Q2 2020

Aug 14, 2020
BUY
$7.95 - $18.81 $32,650 - $77,252
4,107 Added 61.24%
10,813 $176,000
Q1 2020

May 14, 2020
SELL
$6.45 - $14.04 $7,423 - $16,160
-1,151 Reduced 14.65%
6,706 $64,000
Q4 2019

Feb 13, 2020
BUY
$12.97 - $15.94 $16,484 - $20,259
1,271 Added 19.3%
7,857 $108,000
Q3 2019

Nov 13, 2019
BUY
$14.75 - $20.87 $10,103 - $14,295
685 Added 11.61%
6,586 $100,000
Q2 2019

Aug 14, 2019
BUY
$14.71 - $19.79 $6,016 - $8,094
409 Added 7.45%
5,901 $116,000
Q1 2019

May 15, 2019
BUY
$13.73 - $16.87 $4,352 - $5,347
317 Added 6.13%
5,492 $91,000
Q4 2018

Feb 15, 2019
BUY
$10.6 - $17.49 $9,783 - $16,143
923 Added 21.71%
5,175 $73,000
Q3 2018

Nov 20, 2018
BUY
$16.65 - $21.85 $8,641 - $11,340
519 Added 13.9%
4,252 $74,000
Q2 2018

Aug 10, 2018
SELL
$14.8 - $18.8 $1,154 - $1,466
-78 Reduced 2.05%
3,733 $68,000
Q1 2018

May 17, 2018
SELL
$14.5 - $23.4 $18,038 - $29,109
-1,244 Reduced 24.61%
3,811 $71,000
Q4 2017

Feb 13, 2018
BUY
$13.5 - $16.65 $68,242 - $84,165
5,055
5,055 $79,000

Others Institutions Holding KURA

# of Institutions
214
Shares Held
81.2M
Call Options Held
900K
Put Options Held
228K
View Full List

About Kura Oncology, Inc.

KURA Quotes by TradingView
  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $749M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email